Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades

Hubbard, Andrea K.; Rothlein, Robert

doi:10.1016/s0891-5849(00)00223-9

Cited by 533 publications

(407 citation statements)

References 58 publications

Supporting

Mentioning

370

Contrasting

Unclassified

Order By: Relevance

“…The increases observed in sVCAM-1 and sICAM-1 levels probably reflect an increased level of endothelial cell adhesion molecule expression and activation in patients and an increased capacity for the adhesion of sickle erythrocytes and leukocytes to the endothelium. Expression of ICAM-1 on endothelial cells may be increased by the presence of increased levels of cytokines, such as TNFa, IL-1, IL-4, and interferon g, in the plasma [10].…”

Section: Discussionmentioning

confidence: 99%

Increased levels of soluble ICAM‐1 in the plasma of sickle cell patients are reversed by hydroxyurea

et al. 2004

View full text Add to dashboard Cite

Increased adhesive events between the blood vessel endothelium and red and white cells play a central role in the initiation of vasoocclusive crisis in sickle cell disease (SCD). Soluble VCAM-1 levels are increased in the plasma of sickle cell patients and may be reduced during hydroxyurea (HU) therapy. Reports regarding any changes in soluble ICAM-1 (sICAM-1) levels in sickle cell patients, however, are conflicting, and as yet no beneficial effect of HU upon levels has been observed. Thus, we sought to thoroughly investigate changes in sICAM-1 levels in SCD patients and the effect of HU therapy (20-30 mg/kg/day). Plasma sVCAM-1 levels were significantly higher in steady-state SCD patients than in normal controls (766 ± 86 ng/mL vs. 325 ± 38 ng/mL, respectively, P < 0.0001). sVCAM-1 levels were decreased in patients on HU therapy (543 ± 69 ng/mL) compared to those not taking HU; however, this difference was not significant. Plasma sICAM-1 levels were significantly increased in steady-state SCD patients compared to normal individuals (285 ± 20 ng/mL vs. 202 ± 16 ng/mL, respectively, P = 0.002), and HU therapy significantly reduced sICAM-1 levels in patients (217 ± 12, P = 0.027) to levels approaching those of healthy individuals. sVCAM-1 levels inversely correlated with fetal hemoglobin levels in SCD patients, while a nonsignificant inverse trend was observed between sICAM-1 levels and fetal hemoglobin. In conclusion, plasma sICAM-1 levels were significantly increased in SCD patients, and this increase was reversed by hydroxyurea therapy, possibly reflecting reduced endothelial activation in patients taking HU. Such an event may benefit patients by reducing adhesive interactions between white cells and the endothelium. Am.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased levels of soluble ICAM‐1 in the plasma of sickle cell patients are reversed by hydroxyurea

et al. 2004

View full text Add to dashboard Cite

show abstract

“…In antigen presenting cells including macrophages, ICAM-1 participates in cell-cell interactions during antigen presentation while in other cell types ICAM-1 functions in microbial pathogenesis and as a signal transduction molecule. 25,26 Physiologically, ICAM-1 is expressed at a low basal level, 27 however during inflammatory and immune responses, ICAM-1 level increased substantially and aberrantly at sites of inflammation contributing to a number of inflammation-related diseases and injuries such as endotoxin-induced airway disease 28,29 and asthma, 27,30 arthritis, 31 ulcerative colitis 32 and chronic cholangiopathies. 21 In cancer, ICAM-1 has been mainly implicated in local inflammatory tumor microenvironment, 33 tumor progression and metastasis.…”

Section: Discussionmentioning

confidence: 99%

Inducible RasGEF1B circular RNA is a positive regulator of ICAM-1 in the TLR4/LPS pathway

et al. 2016

View full text Add to dashboard Cite

Circular RNAs (circRNAs) constitute a large class of RNA species formed by the back-splicing of co-linear exons, often within protein-coding transcripts. Despite much progress in the field, it remains elusive whether the majority of circRNAs are merely aberrant splicing by-products with unknown functions, or their production is spatially and temporally regulated to carry out specific biological functions. To date, the majority of circRNAs have been cataloged in resting cells. Here, we identify an LPS-inducible circRNA: mcircRasGEF1B, which is predominantly localized in cytoplasm, shows cell-type specific expression, and has a human homolog with similar properties, hcircRasGEF1B. We show that knockdown of the expression of mcircRasGEF1B reduces LPS-induced ICAM-1 expression. Additionally, we demonstrate that mcircRasGEF1B regulates the stability of mature ICAM-1 mRNAs. These findings expand the inventory of functionally characterized circRNAs with a novel RNA species that may play a critical role in fine-tuning immune responses and protecting cells against microbial infection.

show abstract

“…However, an examination across multiple, high performing rules in the evolved population revealed a consistent pattern of ICAM1 being up-regulated relative to MAP2K6 which was subsequently up-regulated relative to KDR. Moreover, ICAM1 and MAP2K6 are both in the ICAM1 pathway, which has been reported as being associated with cancer progression, while KDR has been reported as being associated with the vascularization supporting tumors (Hubbard and Rothlein 2000). This demonstrates both the ability of genetic programming to find and quantify relationships as well as discovering novel interactions.…”

Section: Genomic Studiesmentioning

confidence: 94%

Applications of genetic programming in cancer research

Worzel

Almal

et al. 2009

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

The theory of Darwinian evolution is the fundamental keystones of modern biology. Late in the last century, computer scientists began adapting its principles, in particular natural selection, to complex computational challenges, leading to the emergence of evolutionary algorithms. The conceptual model of selective pressure and recombination in evolutionary algorithms allows scientists to efficiently search high dimensional space for solutions to complex problems. In the last decade, genetic programming has been developed and extensively applied for analysis of molecular data to classify cancer subtypes and characterize the mechanisms of cancer pathogenesis and development. This article reviews current successes using genetic programming and discusses its potential impact in cancer research and treatment in the near future.

show abstract

Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades

Cited by 533 publications

References 58 publications

Increased levels of soluble ICAM‐1 in the plasma of sickle cell patients are reversed by hydroxyurea

Increased levels of soluble ICAM‐1 in the plasma of sickle cell patients are reversed by hydroxyurea

Inducible RasGEF1B circular RNA is a positive regulator of ICAM-1 in the TLR4/LPS pathway

Applications of genetic programming in cancer research

Contact Info

Product

Resources

About